𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?

✍ Scribed by L. Marignol; T. Robson; H. O. McCarthy; J. Worthington; M. M. Murray; D. Hollywood; M. Lawler; D. G. Hirst

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
195 KB
Volume
10
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Radiation therapy is a treatment modality routinely used in cancer management so it is not unexpected that radiation‐inducible promoters have emerged as an attractive tool for controlled gene therapy. The human tissue plasminogen activator gene promoter (t‐PA) has been proposed as a candidate for radiogenic gene therapy, but has not been exploited to date. The purpose of this study was to evaluate the potential of this promoter to drive the expression of a reporter gene, the green fluorescent protein (GFP), in response to radiation exposure.

Methods

To investigate whether the promoter could be used for prostate cancer gene therapy, we initially transfected normal and malignant prostate cells. We then transfected HMEC‐1 endothelial cells and ex vivo rat tail artery and monitored GFP levels using Western blotting following the delivery of single doses of ionizing radiation (2, 4, 6 Gy) to test whether the promoter could be used for vascular targeted gene therapy.

Results

The t‐PA promoter induced GFP expression up to 6‐fold in all cell types tested in response to radiation doses within the clinical range.

Conclusions

These results suggest that the t‐PA promoter may be incorporated into gene therapy strategies driving therapeutic transgenes in conjunction with radiation therapy. Copyright © 2008 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Use of the radiation-inducible WAF1 prom
Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment
✍ Jenny Worthington; Helen O. McCarthy; Eimear Barrett; Catherine Adams; Tracy Rob 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

## Abstract ## Background Inducible nitric oxide synthase (iNOS) gene therapy has been identified as a potential anti‐tumour strategy. A major problem common to most gene therapy strategies is targeting of treatment to the tumour volume. In this study we report on the use of the X‐ray‐inducible WA

A promoter element of the CD-RAP gene is
A promoter element of the CD-RAP gene is required for repression of gene expression in non-cartilage tissues in vitro and in vivo
✍ Ken Okazaki; Hua Yu; Sherri R. Davies; Toshihiro Imamura; Linda J. Sandell 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract The cartilage‐derived retinoic acid‐sensitive protein (CD‐RAP) gene is expressed predominately in cartilage. Previous studies in transgenic mice have shown that the DNA promoter segment from −2,251 bp to −2,068 bp of the CD‐RAP gene contains elements critical for gene expression. Subseq

Gene-directed enzyme prodrug therapy for
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease
✍ Rosetta Martiniello-Wilks; Allison Dane; Dale J. Voeks; Geetha Jeyakumar; Elin M 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

## Abstract ## Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the __E. coli__ enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludar

A novel approach for gene therapy: engra
A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation
✍ Janik Adriaansen; Margriet J. Vervoordeldonk; Sandra Vanderbyl; Gary de Jong; Pa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

## Background: Rheumatoid arthritis is characterized by inflammation of the synovial tissue. high systemic doses are necessary to achieve therapeutic levels of anti-rheumatic drugs in the joints. gene transfer might provide a more efficient delivery system for genes encoding therapeutic proteins.